Anti-tuberculosis drug delivery for tuberculous bone defects

Expert Opin Drug Deliv. 2021 Dec;18(12):1815-1827. doi: 10.1080/17425247.2021.2005576. Epub 2022 Jan 3.

Abstract

Introduction: Traditional therapy methods for treating tuberculous bone defects have several limitations. Furthermore, systemic toxicity and disease recurrence in tuberculosis (TB) have not been effectively addressed.

Areas covered: This review is based on references from September 1998 to September 2021 and summarizes the classification and drug-loading methods of anti-TB drugs. The application of different types of biological scaffolds loaded with anti-TB drugs as a novel drug delivery strategy for tuberculous bone defects has been deeply analyzed. Furthermore, the limitations of the existing studies are summarized.

Expert opinion: Loading anti-TB drugs into the scaffold through various drug-loading techniques can effectively improve the efficiency of anti-TB treatment and provide an effective means of treating tuberculous bone defects. This methodology also has good application prospects and provides directions for future research.

Keywords: Anti-tuberculosis; drug delivery; osteogenesis; target therapy; tuberculous bone defect.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antitubercular Agents*
  • Drug Delivery Systems
  • Humans
  • Tuberculosis* / drug therapy

Substances

  • Antitubercular Agents